Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry

Hepatocellular adenomas (HCA) with activated β‐catenin present a high risk of malignant transformation. To permit robust routine diagnosis to allow for HCA subtype classification, we searched new useful markers. We analyzed the expression of candidate genes by quantitative reverse transcription polymerase chain reaction QRT‐PCR followed by immunohistochemistry to validate their specificity and sensitivity according to hepatocyte nuclear factor 1 alpha (HNF1α) and β‐catenin mutations as well as inflammatory phenotype. Quantitative RT‐PCR showed that FABP1 (liver fatty acid binding protein) and UGT2B7 were downregulated in HNF1α‐inactivated HCA (P ≤ 0.0002); GLUL (glutamine synthetase) and GPR49 overexpression were associated with β‐catenin–activating mutations (P ≤ 0.0005), and SAA2 (serum amyloid A2) and CRP (C‐reactive protein) were upregulated in inflammatory HCA (P = 0.0001). Immunohistochemistry validation confirmed that the absence of liver‐fatty acid binding protein (L‐FABP) expression rightly indicated HNF1α mutation (100% sensitivity and specificity), the combination of glutamine synthetase overexpression and nuclear β‐catenin staining were excellent predictors of β‐catenin–activating mutation (85% sensitivity, 100% specificity), and SAA hepatocytic staining was ideal to classify inflammatory HCA (91% sensitivity and specificity). Finally, a series of 93 HCA was unambiguously classified using our 4 validated immunohistochemical markers. Importantly, new associations were revealed for inflammatory HCA defined by SAA staining with frequent hemorrhages (P = 0.003), telangiectatic phenotype (P < 0.001), high body mass index, and alcohol intake (P ≤ 0.04). Previously described associations were confirmed and in particular the significant association between β‐catenin–activated HCA and hepatocellular carcinomas (HCC) at diagnosis or during follow‐up (P < 10−5). Conclusion: We refined HCA classification and its phenotypic correlations, providing a routine test to classify hepatocellular adenomas using simple and robust immunohistochemistry. (HEPATOLOGY 2007.)

[1]  C. de Toma,et al.  Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. , 2007, Cancer research.

[2]  L. Terracciano,et al.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.

[3]  J. Zucman‐Rossi,et al.  Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. , 2007, Journal of hepatology.

[4]  J. Zucman‐Rossi,et al.  Inflammatory syndrome with liver adenomatosis: the beneficial effects of surgical management , 2007, Gut.

[5]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[6]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[7]  C. de Toma,et al.  Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. , 2006, Journal of hepatology.

[8]  V. Paradis,et al.  Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. , 2006, Human pathology.

[9]  T. Roskams,et al.  Glypican-3 Expression Distinguishes Small Hepatocellular Carcinomas From Cirrhosis, Dysplastic Nodules, and Focal Nodular Hyperplasia-like Nodules , 2006, The American journal of surgical pathology.

[10]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[11]  J. Zucman‐Rossi,et al.  Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. , 2005, Gastroenterology.

[12]  Cristel G. Thomas,et al.  Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas , 2005 .

[13]  Cristel G. Thomas,et al.  Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. , 2005, Human molecular genetics.

[14]  M. Wolverson,et al.  Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. , 2005, Seminars in liver disease.

[15]  L. Bianchi.  Glycogen storage disease I and hepatocellular tumours , 2005, European Journal of Pediatrics.

[16]  B. Alter,et al.  Androgens and liver tumors: Fanconi's anemia and non‐Fanconi's conditions , 2004, American journal of hematology.

[17]  V. Paradis,et al.  Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. , 2004, Gastroenterology.

[18]  J. Zucman‐Rossi,et al.  Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. , 2003, Gastroenterology.

[19]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[20]  S. Hirohashi,et al.  Overexpression of orphan G‐protein–coupled receptor, Gpr49, in human hepatocellular carcinomas with β‐catenin mutations , 2003, Hepatology.

[21]  Y. Jeng,et al.  p53 gene and Wnt signaling in benign neoplasms: β‐catenin mutations in hepatic adenoma but not in focal nodular hyperplasia , 2002, Hepatology.

[22]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[23]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[24]  J. Ward,et al.  Regulation of the Liver Fatty Acid-binding Protein Gene by Hepatocyte Nuclear Factor 1α (HNF1α) ALTERATIONS IN FATTY ACID HOMEOSTASIS INHNF1α-DEFICIENT MICE , 2000 .

[25]  P. Mackenzie,et al.  Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. , 2000, Molecular pharmacology.

[26]  J. Ward,et al.  Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1alpha (HNF1alpha). Alterations in fatty acid homeostasis in HNF1alpha-deficient mice. , 2000, The Journal of biological chemistry.

[27]  M. Odiévre,et al.  Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. , 1997, Journal of pediatric gastroenterology and nutrition.

[28]  S. Bala,et al.  Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. , 1997, Gastroenterology.

[29]  J. Bilbao,et al.  Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[30]  E. Schiff,et al.  Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. , 1986, Annals of internal medicine.

[31]  C. Degott,et al.  Liver adenomatosis. An entity distinct from liver adenoma? , 1985, Gastroenterology.

[32]  D. V. van Thiel,et al.  Hepatic adenoma associated with portasystemic shunting in a young woman. , 1979, Digestion.

[33]  S. Goldfarb,et al.  Sex hormones and hepatic neoplasia. , 1976, Cancer research.

[34]  B. Portmann,et al.  Histological evidence of carcinoma in a hepatic tumour associated with oral contraceptives. , 1975, British medical journal.